Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

Pharmacoecon Open. 2022 Nov;6(6):899. doi: 10.1007/s41669-022-00372-0.

Authors

David Elsea¹, Lin Fan², Adela Mihai³, Fadoua El Moustaid¹, Daniel Simmons⁴, Matthew Monberg⁵, Dominic Muston⁶

Affiliations

¹ Formerly of Lumanity, Inc., Bethesda, MD, 20814, USA.
² Formerly of Merck & Co., Inc., Rahway, NJ, 07065, USA.
³ AstraZeneca, Cambridge, UK.
⁴ AstraZeneca, Gaithersburg, MD, USA.
⁵ Merck & Co., Inc., Rahway, NJ, 07065, USA.
⁶ Merck & Co., Inc., Rahway, NJ, 07065, USA. dominic.muston@merck.com.

No abstract available

Publication types

Published Erratum